description: Protocols: The SUM190 BC cell line was kindly provided by Dr Ethier (https://sumlineknowledgebase.com/) Tumor RNAs were extracted from sensitive and resistant pre-clinical models and controlled on Agilent Bioanalyzer (Agilent Technologies, Massy, France) cDNA was synthetized by random hexamer primers and reverse transcriptase (Superscript II, Life Technologies). Next, end repair and 3′ ends adenylation of the fragments were performed. Bar-coded adapters were ligated to the cDNA fragments and a PCR reaction was performed to produce the sequencing libraries. The quality check of libraries and quantification were performed using Tape station High sensitivity D1000
attributes.tag: ENA first public
attributes.value: 2022-05-14
attributes.tag: ENA last update
attributes.value: 2022-05-14
attributes.tag: External Id
attributes.value: SAMEA14321737
attributes.tag: INSDC center alias
attributes.value: INSERM
attributes.tag: INSDC center name
attributes.value: INSERM
attributes.tag: INSDC first public
attributes.value: 2022-05-14T00:11:56Z
attributes.tag: INSDC last update
attributes.value: 2022-05-14T00:11:56Z
attributes.tag: INSDC status
attributes.value: public
attributes.tag: Submitter Id
attributes.value: E-MTAB-11682:Sample 2
attributes.tag: broker name
attributes.value: ArrayExpress
attributes.tag: cell line
attributes.value: SUM190
attributes.tag: common name
attributes.value: human
attributes.tag: disease
attributes.value: breast cancer
attributes.tag: genotype
attributes.value: Nectin-4 ADC resistant
attributes.tag: organism part
attributes.value: mammary gland
attributes.tag: sample name
attributes.value: E-MTAB-11682:Sample 2
attributes.tag: sex
attributes.value: female